Latest Health News

Medical Developments International reported a strong start to FY26 with significant revenue growth driven by increased Penthrox volumes and pricing improvements in Australia, alongside steady European demand and progress on paediatric label approvals.

DPM Metals reports solid third quarter production growth at its Bulgarian mines and steady progress integrating the newly acquired Vareš operation, setting the stage for future expansion.

MedAdvisor Limited will have its trading suspension lifted on 10 October 2025 following the lodgement of its annual financial report, marking a key moment for investors.

Discovery Alaska Limited has detailed its exploration expenditures and strategic pivot from Alaskan projects to new US acquisitions, affirming its financial health and operational sufficiency to maintain its ASX listing.

EVE Health Group has raised $1.1 million to accelerate the commercial rollout of its innovative pharmaceutical products Dyspro and Libbo, signaling strong investor confidence in its growth strategy.

LDR Assets, led by the Lederer Family Office, updates its $0.70 per security takeover offer for Elanor Commercial Property Fund, highlighting management concerns and urging investors to accept before the 13 October deadline.

The ACCC has approved Elders Limited’s acquisition of Delta Agribusiness, contingent on Elders divesting six Delta retail stores in Western Australia to preserve local competition.

EDU Holdings Limited is set to renew its on-market share buyback program, aiming to repurchase up to 14.4 million shares over the next year, continuing its strategy to enhance shareholder value.

Anatara Lifesciences has completed the first tranche of its two-part share placement, issuing over 33 million ordinary shares to professional investors. This move marks a significant step in the company’s capital raising efforts amid ongoing product development.

AKORA Resources has successfully completed a $2.9 million capital raise and commenced a trenching program at its flagship Bekisopa Iron Ore Project in Madagascar, reinforcing strong local and governmental support as it progresses towards production.

Adamantem Capital Management has completed its due diligence on Apiam Animal Health and extended its exclusivity period to negotiate a potential $0.87 per share acquisition. The deal remains subject to approvals and binding agreements.

Immuron Limited has taken a significant step forward by submitting an Investigational New Drug application to the FDA for IMM-529, targeting Clostridioides difficile infection. The company aims to start Phase 2 trials in early 2026, addressing a critical unmet need in infectious disease treatment.